Why Eli Lilly’s Insulin Price Cap Announcement Matters
Insulin manufacturer Eli Lilly follows the government’s lead with a $35 price cap. Will manufacturers follow suit?
Drug safety and effectiveness, pharmaceutical pricing and policy, antibiotics and antimicrobial resistance, and more
Explore the latest public health research and insights about drugs.
Insulin manufacturer Eli Lilly follows the government’s lead with a $35 price cap. Will manufacturers follow suit?
Looking for prominent public health experts in the field of drugs? They’re here at the Bloomberg School of Public Health.
Joshua Sharfstein, MD, works to develop and promote public health strategies, healthcare payment approaches, and regulatory policies that advance health and equity.
G. Caleb Alexander, MD, MS, is a practicing internist and epidemiologist focused on maximizing the use, safety, and effectiveness of prescription medicines.
Gerard Anderson, PhD, works with policymakers to control health care spending.
Aditi Sen, PhD, MA, is a health economist working to design and implement payment and delivery systems that improve quality of and access to care for all Americans.